SOLTF Stock - Nxera Pharma Co., Ltd.
Unlock GoAI Insights for SOLTF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $28.84B | $12.77B | $15.57B | $17.71B | $8.84B |
| Gross Profit | $21.22B | $9.66B | $14.64B | $16.78B | $8.08B |
| Gross Margin | 73.6% | 75.7% | 94.1% | 94.7% | 91.4% |
| Operating Income | $-5,423,000,000 | $-9,526,000,000 | $3.44B | $3.77B | $928.00M |
| Net Income | $-4,838,000,000 | $-7,193,000,000 | $382.00M | $1.02B | $1.48B |
| Net Margin | -16.8% | -56.3% | 2.5% | 5.7% | 16.7% |
| EPS | $-53.95 | $-87.18 | $4.67 | $12.53 | $18.78 |
Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company's development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders. It is also involved in the development of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; and other discovery and preclinical stage drugs. Nxera Pharma Co., Ltd. has a strategic collaboration with AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily. Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Tokyo, Japan.
Visit WebsiteEarnings History & Surprises
SOLTFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 30, 2026 | — | — | — | — |
Q1 2026 | Feb 13, 2026 | — | — | — | — |
Q4 2025 | Oct 31, 2025 | $0.15 | $-0.00 | -100.6% | ✗ MISS |
Q3 2025 | Aug 8, 2025 | $0.12 | $-0.18 | -247.1% | ✗ MISS |
Q2 2025 | May 2, 2025 | $-0.27 | $-0.06 | +78.9% | ✓ BEAT |
Q1 2025 | Feb 11, 2025 | $0.05 | $-0.09 | -279.1% | ✗ MISS |
Q4 2024 | Nov 1, 2024 | $0.00 | $0.09 | +4674.0% | ✓ BEAT |
Q3 2024 | Aug 9, 2024 | $0.00 | $-0.10 | -19846.0% | ✗ MISS |
Q2 2024 | May 9, 2024 | $0.12 | $-0.24 | -294.1% | ✗ MISS |
Q1 2024 | Mar 27, 2024 | $0.03 | $-0.02 | -163.1% | ✗ MISS |
Q3 2023 | Sep 30, 2023 | $0.21 | $-0.40 | -295.1% | ✗ MISS |
Q2 2023 | Jun 30, 2023 | — | $-0.06 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.13 | — | — |
Q1 2023 | Feb 14, 2023 | — | $44.03 | — | — |
Q4 2022 | Nov 11, 2022 | — | $3.82 | — | — |
Q3 2022 | Aug 10, 2022 | — | $-17.95 | — | — |
Q2 2022 | May 13, 2022 | — | $-25.39 | — | — |
Q1 2022 | Feb 10, 2022 | — | $28.21 | — | — |
Q4 2021 | Nov 11, 2021 | — | $5.80 | — | — |
Q3 2021 | Aug 12, 2021 | — | $-14.11 | — | — |
Latest News
Frequently Asked Questions about SOLTF
What is SOLTF's current stock price?
What is the analyst price target for SOLTF?
What sector is Nxera Pharma Co., Ltd. in?
What is SOLTF's market cap?
Does SOLTF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to SOLTF for comparison